LifeMD Offers Novo Nordisk’s Ozempic For $499 A Month To Eligible Patients
Synopsis
Eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, will have access to Ozempic through LifeMD’s platform for $499 a month.
LifeMD Inc. (LFMD) announced on Tuesday that it has partnered with Novo Nordisk AS (NVO) to offer Ozempic through an integration with NovoCare Pharmacy to eligible patients.
According to the company’s announcement, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, now have direct access to all FDA-approved dose strengths of Ozempic within LifeMD’s end-to-end virtual care platform for $499 a month.
Get updates to this story developing <directly on Stocktwits<.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.